51 results about "Obesity prevention" patented technology

Provided herein, in part, is a method of treating or preventing obesity or an obesity-related disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a small molecule inhibitor of an Activin receptor Type II.

One aspect of the present invention relates to: a conjugate comprising a peptide of a novel sequence and glycyrrhizin; and a pharmaceutical composition for preventing or treating obesity, the composition comprising the conjugate. The conjugate and composition comprising same according to one aspect were found to inhibit hypertrophy of fat cells, increase the cell membrane expression level of ATP-binding cassette transporter A1 (ABCA1), and reduce the secretion of tumor necrosis factor-α (TNF-α). In addition, the conjugate and composition comprising same were found to remain in a greater amount in the blood and have better pharmacokinetic properties than glycyrrhizin used by itself, and thus can be used in the obesity prevention and / or treatment market / industry.

This disclosure provides a vaccine including a peptide with the amino acid sequence of SEQ ID NO:1; a nucleotide having the sequence of SEQ ID NO:2; or a ribonucleotide having the sequence of SEQ ID NO:3. In certain embodiments, the vaccine further comprises a buffer and / or an adjuvant.

The invention discloses application of lactobacillus fermentum E1 in preparation of fat-reducing and weight-losing products, and belongs to the technical field of microorganisms. The lactobacillus fermentum E1 disclosed by the invention can remarkably promote fat metabolism in the zebra fish body in vivo, can remarkably reduce the content of triglyceride and total cholesterol in the hyperlipidemia zebra fish body, and has the potential of being applied to losing weight and regulating the blood fat level; theoretical reference and guidance basis are provided for developing probiotic preparations for treating or preventing obesity and hyperlipidemia by using the lactobacillus fermentum E1.

The present invention relates to a crystalline form I represented by Formula 1, which may be characterized by XRD patterns, DSC profiles, and / or TGA profiles, a method for preparing the same, and a pharmaceutical composition comprising the same, useful for the treatment of prevention of obesity, diabetes, inflammation, or erectile dysfunction. (see formula 1) wherein R1 is C2-C5 alkyl.

A composition comprising a soy protein isolate, a soy fibre, a phospholipid, and a carbohydrate for use in the treatment or prevention of obesity, type 2 diabetes or cardiovascular disorders, wherein the composition is administered together with a first pharmaceutical composition comprising an appetite suppressant agent.

The present invention provides a compound represented by formula (I) or formula (II), or a pharmaceutically acceptable salt, prodrug, stereoisomer, stereoisomer mixture, tautomer, deuterated compound, hydrate or solvate thereof, and a use thereof. The compound has a good agonistic effect on APJ receptors, and can be used for treating and / or preventing diseases such as obesity, hypertension, pulmonary hypertension, and sarcopenia.

The invention provides a compound as shown in a formula (I) or pharmaceutically acceptable salt, prodrug, stereoisomer, tautomer, deuterated compound, hydrate or solvate thereof, and a preparation method and application of the compound or the pharmaceutically acceptable salt, prodrug, stereoisomer, tautomer, deuterated compound, hydrate or solvate thereof. The compound has a good agonistic effect on an APJ receptor, and can be used for treating and / or preventing obesity, hypertension, pulmonary arterial hypertension, sarcopenia and other diseases.

The present invention relates to RNAi constructs for reducing expression of the CNR1 gene. Methods of using such RNAi constructs to reduce visceral adiposity and treat or prevent obesity and obesity-related conditions, such as type 2 diabetes, fatty liver disease, steatohepatitis, and cardiovascular disease, are also described.

The invention discloses application of lactobacillus gasseri LS03 in preparation of fat-reducing and weight-losing products, and belongs to the technical field of microorganisms. The lactobacillus gasseri LS03 disclosed by the invention can remarkably promote fat metabolism in a zebra fish body in vivo, can remarkably reduce the content of triglyceride and total cholesterol in a hyperlipidemia zebra fish body, has the potential of being applied to losing weight and regulating the blood fat level, and can be used for preventing and treating hyperlipidemia. The lactobacillus gasseri LS03 provides theoretical reference and guidance basis for developing probiotic preparations for treating or preventing obesity and hyperlipidemia by utilizing the lactobacillus gasseri LS03.

The present invention provides a novel method that can improve or maintain muscle quantity or muscle strength, and a novel method that can prevent obesity, or lower body fat percentage, or lower body fat quantity, or lower fat removal quantity. The proteoglycan used in the present invention is obtained by a method for producing the proteoglycan, comprising the steps of immersing a biological sample comprising the proteoglycan in an aqueous solution of a surfactant and collecting the solution after the immersion.

The present invention relates to compounds which are for use in the treatment, alleviation or prevention of obesity and / or a disease, disorder or abnormality associated therewith. In a further embodiment, the compounds are for use in reducing neuroinflammation, reducing microgliosis, and / or improving insulin sensitivity, preferably in an obese subject. In another embodiment, the compounds are for use in the treatment, alleviation or prevention of a disease, disorder or abnormality which is responsive to the modulation of IL-17A and / or IL36G. The compounds are NLRP3 inflammasome pathway inhibitors. In particular, the compounds inhibit the activation of a component of the NLRP3 inflammasome pathway. More particularly, the component of the inflammasome pathway is NOD-like receptor (NLR) family, pyrin domain-containing protein 3 (NLRP3) inflammasome, in particular IL-1 beta and / or IL-18 levels are modulated thereby.

To provide polypeptide-containing pharmaceutical compositions.SOLUTION: The invention relates to a pharmaceutical composition comprising a polypeptide, more specifically, a pharmaceutical composition for preventing or treating obesity, diabetes or non-alcoholic fatty liver disease. Th pharmaceutical composition is safe without any side effects such as nausea or vomiting with effects of reducing food intake, enhancing insulin secretion, suppressing gastric emptying, promoting lipolysis, and lowering a level of triglycerides. The invention relates to a polypeptide-containing pharmaceutical composition, medical use of the polypeptide-containing pharmaceutical composition, for example, use in treatment or prevention of obesity, diabetes or non-alcoholic fatty liver disease.SELECTED DRAWING: None

The utility model discloses a dog food putting device, which relates to the technical field of automation control, and comprises a bottom plate, the outer wall of the top of the bottom plate is fixedly connected with a fixing frame, a plurality of grooves are arranged in the fixing frame, the inner wall of the bottom of the bottom plate is fixedly connected with a plurality of putting pipelines, and the putting pipelines are communicated with the grooves. According to the dog food feeding device, through the discharging pipe, when the discharging pipe and the storage tank are completely separated, the baffle on the discharging pipe can gradually seal the storage tank, dog food in the storage tank is prevented from being scattered, then the cover plate and the discharging pipe are in a separated state, and the dog food can be fed into the discharging pipe. According to the automatic feeding device for the dog food, the dog food which falls into the discharging pipe from the storage tank falls into the feeding pipeline from the groove and then falls into the discharging box, so that the effect of automatically feeding the dog food is achieved, the situation that too much or too little feeding possibly occurs due to manual feeding is avoided, the healthy body weight of the dog can be maintained, and the problems of obesity or malnutrition and the like can be prevented.

Provided is use of an MDM2 inhibitor in weight management by inducing weight loss in a subject, as well as the MDM2 inhibitor in the treatment and / or prevention of obesity, dyslipidemia, a non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and / or type 2 diabetes. The present invention further relates to a method for using the MDM2 inhibitor in the use.

The present disclosure provides recombinantly manufactured fusion proteins comprising a GLP-1 protein fragment or an analog thereof linked to a feline Fc fragment. Embodiments include the administration of the fusion proteins to patients and their use as an appetite suppressant, for treatment of obesity, for prevention of obesity, or for treatment of other conditions associated with excess weight in cats. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

The present invention provides a device and method for preventing obesity and regulating body weight using non-invasive blood glucose measurement, the device comprising: a sensing unit that generates lifestyle pattern biological information by detecting motion sensing information and body information; a storage unit that stores biological information, motion standard model information, blood glucose measurement information, and blood glucose measurement synthesis information; a blood glucose measurement unit that measures blood glucose of a user in real time by non-invasive blood glucose measurement to acquire blood glucose measurement information; a personal matching unit that compares the amount of blood glucose measured by the blood glucose measurement unit with blood glucose amount synthesis information stored in the storage unit according to an externally input or preset blood glucose level range and increase / decrease information; a blood glucose level processing unit that outputs a personal matching result in real time using a comparison result of the personal matching unit; and an output unit that outputs the personal matching result output from the blood glucose level processing unit to the outside so that the outside can recognize.

The present invention relates to gene expression signatures, as well as methods and kits using said signatures, for predicting or evaluating the predisposition to obesity in a subject. The signature comprises at least GLUL, SFRP4, ITIH5, GPC1, VGLL3 and C1QTNF1 genes. The methods and kits can be used for selecting a subject susceptible to benefit from prevention against obesity.

The compounds and methods of the present disclosure exhibit induce Ucp1 transcription, enhance of mitochondrial respiration, activate protein kinase A, increase lipolysis, and increase p38 MAPK phosphorylation in cells, particularly brown adipocytes and white adipocytes. They also protect primary cardiomyocytes against hypertrophy induced by adrenergic agonists. Such compounds and methods are useful in the treatment and prevention of conditions such as obesity and associated complex metabolic, endocrine, and hemodynamic changes, as well as related conditions as dyslipidemias, cardiovascular disease, and type 2 diabetes.

The invention discloses application of bifidobacterium breve NX-5 in preparation of fat-reducing and weight-losing products, and belongs to the technical field of microorganisms. The bifidobacterium breve NX-5 disclosed by the invention can remarkably promote fat metabolism in a zebra fish body in vivo, can remarkably reduce the content of triglyceride and total cholesterol in a hyperlipidemia zebra fish body, and has the potential of being applied to losing weight and regulating the blood fat level; theoretical reference and guidance basis are provided for developing probiotic preparations for treating or preventing obesity and hyperlipidemia by utilizing the bifidobacterium breve NX-5.

The invention discloses application of lactobacillus acidophilus LA-03 in preparation of fat-reducing and weight-losing products, and belongs to the technical field of microorganisms. The lactobacillus acidophilus LA-03 disclosed by the invention can remarkably promote fat metabolism in a zebra fish body in vivo, can remarkably reduce the content of triglyceride and total cholesterol in a hyperlipidemia zebra fish body, has the potential of being applied to losing weight and regulating the blood fat level, and can be used for preventing and treating hyperlipidemia. Theoretical reference and guidance basis are provided for developing probiotic preparations for treating or preventing obesity and hyperlipidemia by using the lactobacillus acidophilus LA-03.

The invention discloses a bacterial strain with an effect of preventing and treating obesity and application of the bacterial strain, the bacterial strain is Lactobacillus paracasei Biohalo 27, the bacterial strain is preserved in China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC NO.34917, the preservation number is CGMCC NO.34917, the preservation number is CGMCC NO.34917, the preservation number is CGMCC NO.34917, the preservation number is CGMCC NO.34917, and the preservation number is CGMCC NO.34917. The preservation time is June 16, 2025; according to the invention, a strain with the effect of preventing and treating obesity is obtained by screening, and the lactobacillus paracasei Biohalo 27 plays an anti-obesity role by regulating lipid metabolism, improving insulin sensitivity, inhibiting inflammatory response and relieving liver fatty degeneration; and important experimental basis and theoretical support are provided for application of the novel probiotic preparation in prevention and treatment of obesity and related metabolic diseases.

The invention provides a compound shown in a formula (I) or a formula (II) or pharmaceutically acceptable salt, a prodrug, a stereoisomer, a stereoisomer mixture, a tautomer, a deuterated substance, a hydrate or a solvate of the compound, and application of the compound or the pharmaceutically acceptable salt, the prodrug, the stereoisomer, the stereoisomer mixture, the tautomer, the deuterated substance, the hydrate or the solvate. The compound has a good agonistic effect on an APJ receptor, and can be used for treating and / or preventing obesity, hypertension, pulmonary arterial hypertension, sarcopenia and other diseases.

Salts of hexylamine, for example, hexylamine succinate and tri-hexylamine citrate and their method of production are described. The disclosure also relates to compositions comprising hexyalmine, for example, for reducing appetite in a human subject, treating obesity in a human subject, preventing obesity in a human subject, preventing weight gain in a human subject, increasing fat loss in a human subject, treating an overweight human subject, increasing athletic performance in a human subject, increasing endurance in a human subject, increasing muscle strength in a human subject, improving cognitive function in a human subject, treating ADHD in a human subject, increasing sweating in a human subject, reducing reaction time of a human subject, increasing psychomotor vigilance of a human subject, enhancing memory in a human subject, increasing central nervous system activity in a human subject, and enhancing alertness, attention, concentration, and / or memory in a human subject.

The invention discloses a medicinal and edible composition for preventing obesity as well as a preparation method and application thereof, and relates to the technical field of foods and medicines. The medicinal and edible composition is prepared from the following components in parts by weight: 50 to 500 parts of chlorogenic acid, 10 to 300 parts of bitter gourd protein and 1000 to 10000 parts of apple pectin. According to the invention, the efficiency of intervening the obesity process is improved through a specific formula combination, and the problems of slow effect and low pertinence of obesity prevention caused by various inducements can be avoided through multi-target and multi-channel adjustment.

The present disclosure is directed to engineered probiotic bacteria capable of producing anti-obesity therapeutic molecules. More specifically, bacteria are engineered to express N-lactoyl-phenyalanine (Lac-Phe), an exercise inducible molecule capable of reducing food intake and suppressing obesity, driven by a high-fat diet. Also disclosed are methods of using the engineered bacteria to treat and protect individuals from obesity.

The invention discloses a natural compound complexing agent for preventing obesity and a preparation method thereof, and relates to the technical field of health foods and medicines. The natural compound complexing agent is prepared from the following components in parts by weight: 50 to 500 parts of conjugated linoleic acid, 10 to 300 parts of sophocarpidine, 100 to 2000 parts of L-carnitine and 1000 to 10000 parts of apple pectin. According to the invention, a novel efficient weight-losing scheme is researched and developed by screening natural products and excavating medicinal and edible components, the efficiency of intervening the obesity process is improved by virtue of a specific formula combination, and the problems of slow effect and low pertinence in the obesity prevention process caused by various inducements can be avoided by virtue of multi-target and multi-channel adjustment.

The invention relates to an application of a dual agonist of amylin analogue, gastric inhibitory polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R) in body weight regulation and treatment or prevention of obesity and related diseases.

The invention discloses bifidobacterium adolescentis and application of the bifidobacterium adolescentis in fat reduction. The bifidobacterium adolescentis is preserved in the China General Microbiological Culture Collection Center, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.31381. The bifidobacterium adolescentis has the effects of reducing the body fat rate, reducing weight, inhibiting the body weight rebound after weight loss, maintaining the weight loss effect, improving the blood fat and the like, promotes brown fat to produce heat and promotes white fat to be converted into brown fat, and meanwhile has high safety superior to that of weight-reducing drugs. In addition, when the medicine or food is used for treating and preventing obesity, the total cholesterol and total triglyceride levels are reduced, the liver function is improved, the pancreas health is maintained, the fat cell area is reduced, liver fat infiltration is reduced, the intestinal flora is regulated, and the inflammation level is reduced.

The present disclosure relates to fused heteroaryl lactam compounds of Formula (I) as described herein and to their use in medicine; to pharmaceutical compositions containing them; to processes for their preparation; and to intermediates used in such processes. The fused heteroaryl lactam compounds of Formula (I) and salts thereof may be useful to treat or prevent, for example, obesity, weight gain, and / or T2DM.